Kinomics: approaches and applications
Gespeichert in:
Weitere Verfasser: | , |
---|---|
Format: | Buch |
Sprache: | English |
Veröffentlicht: |
Weinheim
Wiley-VCH Verlag GmbH & Co. KGaA
[2015]
|
Schlagworte: | |
Online-Zugang: | Inhaltstext Inhaltsverzeichnis |
Beschreibung: | XXI, 339 Seiten Illustrationen, Diagramme |
ISBN: | 9783527337651 9783527683031 |
Internformat
MARC
LEADER | 00000nam a22000008c 4500 | ||
---|---|---|---|
001 | BV042928832 | ||
003 | DE-604 | ||
005 | 20160114 | ||
007 | t | ||
008 | 151015s2015 gw a||| |||| 00||| eng d | ||
015 | |a 15,N16 |2 dnb | ||
016 | 7 | |a 1069342939 |2 DE-101 | |
020 | |a 9783527337651 |c (Print) |9 978-3-527-33765-1 | ||
020 | |a 9783527683031 |c (oBook) |9 978-3-527-68303-1 | ||
035 | |a (OCoLC)907550730 | ||
035 | |a (DE-599)DNB1069342939 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
044 | |a gw |c XA-DE-BW | ||
049 | |a DE-20 |a DE-11 | ||
082 | 0 | |a 612.015192 |2 22/ger | |
082 | 0 | |a 540 |2 23 | |
084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
084 | |a WD 5060 |0 (DE-625)148187: |2 rvk | ||
084 | |a 540 |2 sdnb | ||
245 | 1 | 0 | |a Kinomics |b approaches and applications |c edited by Heinz-Bernhard Kraatz and Sanela Martic |
264 | 1 | |a Weinheim |b Wiley-VCH Verlag GmbH & Co. KGaA |c [2015] | |
264 | 4 | |c © 2015 | |
300 | |a XXI, 339 Seiten |b Illustrationen, Diagramme | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
650 | 0 | 7 | |a Enzyminhibitor |0 (DE-588)4152479-2 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Kinasen |0 (DE-588)4268693-3 |2 gnd |9 rswk-swf |
689 | 0 | 0 | |a Kinasen |0 (DE-588)4268693-3 |D s |
689 | 0 | 1 | |a Enzyminhibitor |0 (DE-588)4152479-2 |D s |
689 | 0 | 2 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Kraatz, Heinz-Bernhard |0 (DE-588)131684663 |4 edt | |
700 | 1 | |a Martic, Sanela |0 (DE-588)1078005923 |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, EPUB |z 978-3-527-68305-5 |
776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, MOBI |z 978-3-527-68306-2 |
776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, PDF |z 978-3-527-68304-8 |
856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=5200190&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028355699&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-028355699 |
Datensatz im Suchindex
_version_ | 1806332610385805312 |
---|---|
adam_text |
CONTENTS
LIST OF CONTRIBUTORS XIII
PREFACE XIX
PART I PROTEIN KINASES CELL SIGNALING 1
1 GLOBAL APPROACHES TO UNDERSTANDING PROTEIN KINASE FUNCTIONS 3
JENNIFER L. GORMAN AND
JAMES R. WOODGETT
1.1 A BRIEF HISTORY OF THE STRUCTURE OF THE HUMAN KINOME 3
1.1.1 AGC KINASES 3
1.1.2 THE CAMK FAMILY 5
1.1.3 CMGC FAMILY KINASES 5
1.1.4 STE FAMILY KINASES 7
1.1.5 TYROSINE KINASES 7
1.1.6 CASEIN KINASES
8
1.1.7 TYROSINE KINASE-LIKE FAMILY 9
1.1.8 RGC KINASES 9
1.1.9 ATYPICAL/OTHER PROTEIN KINASES 9
1.2 WHY STUDY PROTEIN KINASES - THEIR ROLES IN DISEASE 10
1.2.1 NEURODEGENERATIVE DISEASE 10
1.2.2 HALLMARKS OF CANCER 13
1.3 METHODOLOGY FOR ASSESSMENT OF PROTEIN KINASE FUNCTIONS 16
1.3.1 MASS SPECTROMETRY 16
1.3.2 FLUORESCENCE RESONANCE ENERGY TRANSFER 18
1.3.3 ASSESSMENT OF KINASE FUNCTIONS IN VITRO: GENETIC AND CHEMICAL 20
1.3.4 FUNCTIONAL ASSESSMENT OF KINASE FUNCTION IN VIVO: ANIMAL
MODELS 22
1.3.5 CRISPR/CAS9 GENOMIC RECOMBINEERING 25
1.4 FINAL THOUGHTS 28
ACKNOWLEDGMENTS 29
REFERENCES 29
HTTP://D-NB.INFO/1069342939
VII CONTENTS
2 "GENUINE" CASEIN KINASE (FAM20C): THE MOTHER OF THE
PHOSPHOSECRETOME 47
GIORGIO
COZZA,
VINCENT S. TAGLIABRACCI,
JACK E. DIXON, AND LORENZO A. PINNA
2.1 INTRODUCTION 47
2.2 EARLY DETECTION OF THE PS-X-E MOTIF IN SECRETED
PHOSPHOPROTEINS 48
2.3 CK1 AND CK2 ARE NOT GENUINE CASEIN KINASES 50
2.4 POLO-LIKE KINASES: NEWCOMERS IN THE CLUB OF FALSE "CASEIN
KINASES" 51
2.5 CHARACTERIZATION OF AN ORPHAN ENZYME: THE SPECTACULAR
PERFORMANCE OF A PEPTIDE SUBSTRATE 57
2.6 CATALYTIC ACTIVITY OF FAM20C: MECHANISTIC ASPECTS 53
2.7 A KINASE IN NEED OF CONTROL 54
2.7.1 CONSTITUTIVELY ACTIVE OR INACTIVE? 54
2.7.2 A POTENTIAL MEDIATOR OF SPHINGOSINE SIGNALING 55
2.7.3 FAM20C AS A NOVEL REGULATOR OF BLOOD PHOSPHATE
HOMEOSTASIS 56
2.7.4 DOES IT MAKE SENSE TO DEVELOP FAM20C INHIBITORS? 56
2.8 OUTLOOK 57
FUNDING 58
REFERENCES 58
3 CHEMICAL BIOLOGY OF PROTEIN KINASES 63
DAVID MANN
3.1 THE BASIS OF CHEMICAL GENETICS 63
3.2 PROTEIN KINASE CHEMICAL GENETICS 65
3.3 APPLICATIONS FOR AS KINASES 68
3.3.1 SUBSTRATE IDENTIFICATION: GENERAL PHOSPHOPROTEOMICS 69
3.3.2 SUBSTRATE IDENTIFICATION: REFINEMENTS THROUGH THE USE OF AS
KINASES 70
3.3.3 SUBSTRATE IDENTIFICATION IN ACTION: WHAT HAVE WE LEARNED? 73
3.3.4 USE OF SPECIFIC INHIBITORS FOR AS KINASES 75
3.4 CURRENT CHALLENGES 77
3.5 CONCLUSIONS 80
ACKNOWLEDGMENTS 81
REFERENCES 81
4 PROTEIN KINASES AND CASPASES: BIDIRECTIONAL INTERACTIONS IN
APOPTOSIS 85
STEPHANIE A. ZUKOWSKI
AND DAVID W. LITCHFIELD
4.1 INTRODUCTION 85
4.2 APOPTOSIS: CASPASE-DEPENDENT PATHWAYS
86
4.2.1 EXTRINSIC APOPTOSIS
86
4.2.2 CASPASE-DEPENDENT INTRINSIC APOPTOSIS 87
CONTENTS VII
4.3 FUNCTIONAL CROSSTALK BETWEEN PROTEIN KINASES AND
CASPASES
88
4.3.1 DIRECT PHOSPHORYLATION OF CASPASES BY PROTEIN KINASES 89
4.3.1.1 INITIATOR CASPASES 89
4.3.1.2 EXECUTIONER CASPASES 91
4.3.2 CLEAVAGE OF CASPASE SUBSTRATES IS POSITIVELY AND NEGATIVELY
REGULATED BY PROTEIN KINASE PHOSPHORYLATION 91
4.3.3 CASPASE-MEDIATED DEGRADATION OF KINASES AND APOPTOTIC
PROGRESSION 94
4.3.3.1 RHO-ASSOCIATED COILED-COIL-CONTAINING PROTEIN 1 (ROCK1) 94
4.3.3.2 P21-ACTIVATED PROTEIN KINASE 2 (PAK2) 96
4.3.3.3 FOCAL ADHESION KINASE (FAK) 97
4.3.3.4 PROTEIN KINASE AKT 97
4.3.3.5 PROTEIN KINASE C8 (PKC8) 97
4.4 STRATEGIES TO INVESTIGATE GLOBAL CROSSTALK BETWEEN PROTEIN KINASES
AND CASPASES 99
4.4.1 COMPUTATIONAL APPROACHES AND BIOINFORMATICS: INVESTIGATING
OVERLAP BETWEEN PROTEIN KINASE CONSENSUS SITES AND CASPASE
RECOGNITION MOTIFS 99
4.4.2 PROTEOMICS-BASED STRATEGIES TO INVESTIGATE CROSSTALK WITHIN THE
PHOSPHOPROTEOME AND THE CASPASE DEGRADOME 101
4.4.3 REPORTERS TO MONITOR THE SPATIAL AND TEMPORAL DYNAMICS OF
PHOSPHORYLATION AND CASPASE CLEAVAGE IN LIVING CELLS 103
4.5 IMPLICATIONS AND FUTURE PROSPECTS 103
REFERENCES 104
5 THE KINOMICS OF MALARIA 115
MATHIEU BROCHET,
ANDREW B. TOBIN,
OLIVER BILLKER, AND
CHRISTIAN DOERIG
5.1 INTRODUCTION 115
5.1.1 MALARIA PARASITES: HIGHLY DIVERGENT EUKARYOTES 115
5.1.2 POSTTRANSLATIONAL MODIFICATIONS OF PROTEINS: AN ESSENTIAL
MULTIPLIER
OF PROTEOME COMPLEXITY 116
5.2 THE PLASMODIUM KINOME: SALIENT FEATURES 117
5.3 REVERSE GENETICS OF THE PLASMODIUM KINOME 120
5.4 LESSONS FROM PHOSPHOPROTEOMICS 123
5.4.1 PHOSPHORYLATION CASCADES 124
5.4.2 EVIDENCE FOR TYROSINE PHOSPHORYLATION PLASMODIUM 124
5.5 HOST CELL KINOMICS IN MALARIA INFECTION 127
5.6 TARGETING PROTEIN KINASES IN ANTIMALARIAL DRUG DISCOVERY 128
5.6.1 TARGETING THE PARASITE KINOME FOR CURATIVE AND
TRANSMISSION-BLOCKING INTERVENTION 128
5.6.2 TARGETING HOST KINASES? 129
5.7 CONCLUDING REMARKS 130
REFERENCES 130
VIII I CONTENTS
PART II ATP CO-SUBSTRATE DESIGN 137
6 ATP ANALOGS IN PROTEIN KINASE RESEARCH 139
THILANI M. ANTHONY, PAVITHRA M. DEDIGAMA-ARACHCHIGE, D. MAHEEKA
EMBOGAMA, TODD R. FANER,
AHMED E. FOUDA, AND MARY
KAY H. PFLUM
6.1 BASE-MODIFIED ATP ANALOGS 140
6.1.1 C2, C6, AND C8-MODIFIED ATP ANALOGS 141
6.1.2 N6-MODIFIED ATP ANALOGS 141
6.1.2.1 GATEKEEPER AS-KINASE MUTANTS 143
6.1.2.2 MULTIPLY MUTATED AS-KINASES 144
6.1.3 PYRAZOLOPYRIMIDINE ATP ANALOGS 145
6.1.4 TRIAZOLE AND IMIDAZOLE ATP ANALOGS 146
6.1.5 APPLICATIONS OF AS-KINASES AND BASE-MODIFIED ATP ANALOGS 147
6.2 SUGAR-MODIFIED ATP ANALOGS 148
6.3 A- AND P-PHOSPHATE-MODIFIED ATP ANALOGS 149
6.3.1 AMP-PCP ISO
6.3.2 AMP-PNP 151
6.3.3 AMP-CPP 151
6.4 Y-PHOSPHATE-MODIFIED ATP ANALOGS 152
6.4.1 ATPYS 153
6.4.2 ATP-BIOTIN 155
6.4.3 ATP-FLUOROPHORE ANALOGS 157
6.4.4 ATP-FERROCENE 158
6.4.5 ATP-ARYLAZIDE AND ATP-BENZOPHENONE 158
6.4.6 Y-ALKENYL-, Y-ALKYNYL-, Y-AZIDO-ATP 159
6.4.7 BIFUNCTIONAL C8-AZIDO-AND Y-ARYLAZIDO-ATP 160
6.4.8 ATP-ACYL-BIOTIN 160
6.5 CONCLUSIONS 161
REFERENCES 163
7 ELECTROCHEMICAL DETECTION OF PROTEIN KINASE-CATALYZED
PHOSPHORYLATIONS 169
SANELA MARTIC,
SOHA AHMADI,
ZHE SHE,
AND HEINZ-BERNHARD KRAATZ
7.1 INTRODUCTION 169
7.1.1 LABEL-FREE DETECTION OF PHOSPHORYLATION 169
7.1.1.1 GOLD NPS 169
7.1.1.2 SILVER NANOPARTICLES (AGNPS) 173
7.1.1.3 SOLUTION-BASED REDOX PROBES 173
7.1.2 LABELED DETECTION OF PHOSPHORYLATION 175
7.1.2.1 FERROCENE - ATP COSUBSTRATE 175
7.1.2.2 PROBING PROTEIN KINASE BINDING POCKET 177
7.1.2.3 PROBING PHOSPHOPROTEIN BINDING 181
7.1.2.4 PROBING PHOSPHOPROTEIN CONFORMATIONAL CHANGE 182
7.1.2.5 DETECTION OF PROTEIN KINASE INHIBITORS 183
7.1.2.6 UTILITY OF FC-ATP BEYOND ELECTROCHEMISTRY 187
CONTENTS IX
7.2 CONCLUSIONS 187
REFERENCES 190
PART III NEW METHODOLOGIES FOR KINOMICS 193
8 PHOS-TAG TECHNOLOGY FOR KINOMICS 195
EMIKO KINOSHITA-KIKUTA, EIJI KINOSHITA,
AND TOHRU KOIKE
8.1 INTRODUCTION 195
8.2 KINOMICS AND PHOSPHOPROTEOMICS 196
8.3 PHOS-TAG TECHNOLOGY 196
8.4 HIGHLY SENSITIVE DETECTION OF PHOSPHOPEPTIDES AND PHOSPHOPROTEINS
BY THE PHOS-TAG BIOTIN METHOD 197
8.4.1 OUTLINE 197
8.4.2 APPLICATION OF PHOS-TAG BIOTIN IN PEPTIDE MICROARRAYS 197
8.4.3 APPLICATION OF PHOS-TAG BIOTIN IN WESTERN BLOTTING 200
8.5 PROTEIN KINASE ASSAY WITH PHOS-TAG SODIUM DODECYL
SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS 201
8.5.1 OUTLINE 201
8.5.2 QUANTITATIVE ANALYSIS OF ABL TYROSINE KINASE ACTIVITY 202
8.5.3 SIMULTANEOUS DETECTION OF THE ACTIVATION/INACTIVATION OF
EXTRACELLULAR SIGNAL-REGULATED KINASES 204
8.5.4 DIFFERENTIAL ANALYSIS OF THE PHOSPHORYLATION STATUSES OF CELLULAR
PROTEINS IN COMBINATION WITH TWO-DIMENSIONAL DIFFERENCE GEL
ELECTROPHORESIS
206
8.6 CONCLUSION 208
REFERENCES 208
9 DEVELOPMENT OF SPECIES- AND PROCESS-SPECIFIC PEPTIDE KINOME ARRAYS
WITH PRIORITY APPLICATION TO INVESTIGATIONS OF INFECTIOUS DISEASE 211
RYAN ARSENAULT,
BRETT TROST,
ANTHONY KUSALIK,
AND SCOTT NAPPER
9.1 PHOSPHORYLATION-MEDIATED SIGNAL TRANSDUCTION 211
9.1.1 KINOME VERSUS PHOSPHOPROTEOME ANALYSIS 212
9.2 PEPTIDE ARRAYS FOR KINOME ANALYSIS 213
9.2.1 SPECIES-SPECIFIC PEPTIDE ARRAYS FOR KINOME ANALYSIS 214
9.2.2 ANALYSIS OF DATA FROM KINOME MICROARRAYS 217
9.3 INFECTIOUS DISEASE 218
9.3.1 HUMAN INFECTIOUS AGENTS 220
9.3.1.1 MONKEY POX 220
9.3.1.2 PRION DISEASE 221
9.3.2 LIVESTOCK PATHOGENS 222
9.3.2.1 CATTLE 222
9.3.3 APPLICATION OF ARRAYS TO SAMPLES OF GREATER BIOLOGICAL
COMPLEXITY 225
9.3.3.1 KINOME PROFILING OF MAP-INFECTED CALF INTESTINAL TISSUES 226
9.3.3.2 POULTRY 226
X | CONTENTS
9.3.3.3 HONEYBEES AND COLONY COLLAPSE DISORDER (CCD) 227
9.4 CONCLUSIONS 228
REFERENCES 229
10 NEW APPROACHES TO UNDERSTANDING BACTERIAL HISTIDINE KINASE ACTIVITY
AND INHIBITION 233
KAELYN E. WILKE
AND ERIN E. CARLSON
10.1 INTRODUCTION TO TWO-COMPONENT SYSTEM SIGNALING 233
10.2 FOCUS ON BACTERIAL HKS 235
10.3 BACTERIAL HK ACTIVITY 235
10.3.1 SIGNIFICANCE OF UNDERSTANDING HK ACTIVITY 235
10.3.1.1 DETECTION OF HK ACTIVITY: THE MAJOR OBSTACLE 236
10.3.2 CURRENT METHODS FOR STUDYING HK (AND TCS) ACTIVITY 237
10.3.2.1 GENETIC CHARACTERIZATION 237
10.3.2.2 ELUCIDATION OF TCS ACTIVITY AT THE PROTEIN LEVEL 237
10.3.3 THIOPHOSPHORYLATION AS A STABLE ALTERNATIVE 238
10.3.4 BODIPY-FL-ATPYS PROBE 239
10.3.5 FUTURE CHALLENGES AND DEVELOPMENTS 240
10.4 BACTERIAL HK INHIBITION 242
10.4.1 SIGNIFICANCE 242
10.4.2 HK INHIBITORS: PAST AND PRESENT 242
10.4.3 REPURPOSING UNSUCCESSFUL INHIBITORS 245
10.4.4 FUTURE HK INHIBITOR DEVELOPMENTS 248
10.5 OUTLOOK ON TOOLS FOR THE STUDY AND INHIBITION OF BACTERIAL HKS 248
REFERENCES 248
11 METHODS FOR LARGE-SCALE IDENTIFICATION OF PROTEIN KINASE SUBSTRATE
NETWORKS 255
KASSADEE J. KETELAAR
AND IAN S. WALLACE
11.1 INTRODUCTION 255
11.2 COMPUTATIONAL PREDICTION OF PHOSPHORYLATION SITES AND PROTEIN
KINASE-SUBSTRATE RELATIONSHIPS 256
11.3 THE ROLE OF MASS SPECTROMETRY IN IDENTIFYING POSTTRANSLATIONAL
MODIFICATIONS 259
11.4 ANALOG-SENSITIVE KINASES AND OTHER SPECIFIC INHIBITORS 264
11.5 ARRAY-BASED METHODS 266
11.6 SOLUTION-BASED METHODS 269
11.7 FUTURE PERSPECTIVES 271
REFERENCES 272
PART IV KINASE INHIBITION 281
12 DEVELOPING INHIBITORS OF STAT3: TARGETING DOWNSTREAM OF THE KINASES
FOR TREATING DISEASE 283
ANDREW M. LEWIS,
DANIEL P. BALL, RAHUL RANA,
JI SUNG PARK, DAVID ROSA,
PING-SHAN LAI, RODOLFO F.
GOMEZ-BIAGI,
AND PATRICK T. GUNNING
CONTENTS | XI
12.1 INTRODUCTION 283
12.2 STAT3 STRUCTURE AND SIGNALING 284
12.2.1 THE ROLE OF STAT3 IN CANCER 287
12.2.2 STAT3 IN INFLAMMATORY DISEASE 287
12.2.3 STAT3 IN ALZHEIMER'S DISEASE 287
12.3 METHODS FOR DIRECTLY INHIBITING STAT3 288
12.3.1 PEPTIDE INHIBITORS OF STAT3 288
12.3.2 SMALL-MOLECULE INHIBITORS OF STAT3 290
12.3.2.1 INHIBITORS OF THE SH2 DOMAIN 290
12.3.2.2 NATURAL PRODUCT INHIBITORS OF STAT3 294
12.3.3 OLIGONUCLEOTIDE DECOYS OF STAT3 TRANSCRIPTION 296
12.4 CONCLUSION 296
REFERENCES 298
13 METAL COMPOUNDS AS KINASE AND PHOSPHATASE INHIBITORS IN DRUG
DEVELOPMENT: THE ROLE OF THE METAL AND LIGANDS 301
MARIA V. BABAK, MARGAUX AIREY,
AND CHRISTIAN
G. HARTINGER
13.1 INTRODUCTION 301
13.2 KINASE INHIBITORS: FROM IDEAL 3D SHAPES TO KINASE INHIBITOR-DERIVED
LIGANDS IN METAL COMPLEXES 302
13.2.1 METAL-BASED KINASE INHIBITORS: TAKING ADVANTAGE OF THE UNIQUE 3D
STRUCTURE OF METAL COMPLEXES 302
13.2.2 NON-ATP BINDING SITE TARGETING KINASE INHIBITORS 309
13.2.3 METAL-BASED PAULLONES, INDOLOQUINOLINES, AND QUINOXALINONES:
COORDINATION OF BIOACTIVE LIGANDS TO METAL CENTERS 311
13.2.4 FLAVONOL- AND HYDROXYPYRIDONE-DERIVED COMPLEXES: TOWARD
MULTIMODAL ANTICANCER AGENTS 317
13.2.5 EXPLOITING METAL COMPOUNDS FOR SELECTIVE ACTIVATION AND TARGETED
RELEASE OF KINASE INHIBITORS 318
13.3 PHOSPHATASES AND METAL COMPOUNDS 319
13.3.1 THERAPEUTIC POTENTIAL OF METAL-BASED PTP INHIBITORS 319
13.3.2 INORGANIC VANADIUM SALTS AS REVERSIBLE AND IRREVERSIBLE PTP
INHIBITORS 320
13.3.3 VANADIUM COORDINATION COMPOUNDS AS PHOSPHATASE
INHIBITORS 322
13.4 CONCLUSIONS 323
ACKNOWLEDGMENTS 323
REFERENCES 324
INDEX 331 |
any_adam_object | 1 |
author2 | Kraatz, Heinz-Bernhard Martic, Sanela |
author2_role | edt edt |
author2_variant | h b k hbk s m sm |
author_GND | (DE-588)131684663 (DE-588)1078005923 |
author_facet | Kraatz, Heinz-Bernhard Martic, Sanela |
building | Verbundindex |
bvnumber | BV042928832 |
classification_rvk | VS 5350 WD 5060 |
ctrlnum | (OCoLC)907550730 (DE-599)DNB1069342939 |
dewey-full | 612.015192 540 |
dewey-hundreds | 600 - Technology (Applied sciences) 500 - Natural sciences and mathematics |
dewey-ones | 612 - Human physiology 540 - Chemistry and allied sciences |
dewey-raw | 612.015192 540 |
dewey-search | 612.015192 540 |
dewey-sort | 3612.015192 |
dewey-tens | 610 - Medicine and health 540 - Chemistry and allied sciences |
discipline | Chemie / Pharmazie Biologie Medizin |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000008c 4500</leader><controlfield tag="001">BV042928832</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160114</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">151015s2015 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">15,N16</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1069342939</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527337651</subfield><subfield code="c">(Print)</subfield><subfield code="9">978-3-527-33765-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527683031</subfield><subfield code="c">(oBook)</subfield><subfield code="9">978-3-527-68303-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)907550730</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1069342939</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">612.015192</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">540</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WD 5060</subfield><subfield code="0">(DE-625)148187:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">540</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Kinomics</subfield><subfield code="b">approaches and applications</subfield><subfield code="c">edited by Heinz-Bernhard Kraatz and Sanela Martic</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH Verlag GmbH & Co. KGaA</subfield><subfield code="c">[2015]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 339 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kinasen</subfield><subfield code="0">(DE-588)4268693-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Kinasen</subfield><subfield code="0">(DE-588)4268693-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Enzyminhibitor</subfield><subfield code="0">(DE-588)4152479-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kraatz, Heinz-Bernhard</subfield><subfield code="0">(DE-588)131684663</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martic, Sanela</subfield><subfield code="0">(DE-588)1078005923</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-3-527-68305-5</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, MOBI</subfield><subfield code="z">978-3-527-68306-2</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-3-527-68304-8</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=5200190&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028355699&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028355699</subfield></datafield></record></collection> |
id | DE-604.BV042928832 |
illustrated | Illustrated |
indexdate | 2024-08-03T02:43:36Z |
institution | BVB |
isbn | 9783527337651 9783527683031 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028355699 |
oclc_num | 907550730 |
open_access_boolean | |
owner | DE-20 DE-11 |
owner_facet | DE-20 DE-11 |
physical | XXI, 339 Seiten Illustrationen, Diagramme |
publishDate | 2015 |
publishDateSearch | 2015 |
publishDateSort | 2015 |
publisher | Wiley-VCH Verlag GmbH & Co. KGaA |
record_format | marc |
spelling | Kinomics approaches and applications edited by Heinz-Bernhard Kraatz and Sanela Martic Weinheim Wiley-VCH Verlag GmbH & Co. KGaA [2015] © 2015 XXI, 339 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Enzyminhibitor (DE-588)4152479-2 gnd rswk-swf Arzneimitteldesign (DE-588)4278218-1 gnd rswk-swf Kinasen (DE-588)4268693-3 gnd rswk-swf Kinasen (DE-588)4268693-3 s Enzyminhibitor (DE-588)4152479-2 s Arzneimitteldesign (DE-588)4278218-1 s DE-604 Kraatz, Heinz-Bernhard (DE-588)131684663 edt Martic, Sanela (DE-588)1078005923 edt Erscheint auch als Online-Ausgabe, EPUB 978-3-527-68305-5 Erscheint auch als Online-Ausgabe, MOBI 978-3-527-68306-2 Erscheint auch als Online-Ausgabe, PDF 978-3-527-68304-8 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=5200190&prov=M&dok_var=1&dok_ext=htm Inhaltstext DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028355699&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
spellingShingle | Kinomics approaches and applications Enzyminhibitor (DE-588)4152479-2 gnd Arzneimitteldesign (DE-588)4278218-1 gnd Kinasen (DE-588)4268693-3 gnd |
subject_GND | (DE-588)4152479-2 (DE-588)4278218-1 (DE-588)4268693-3 |
title | Kinomics approaches and applications |
title_auth | Kinomics approaches and applications |
title_exact_search | Kinomics approaches and applications |
title_full | Kinomics approaches and applications edited by Heinz-Bernhard Kraatz and Sanela Martic |
title_fullStr | Kinomics approaches and applications edited by Heinz-Bernhard Kraatz and Sanela Martic |
title_full_unstemmed | Kinomics approaches and applications edited by Heinz-Bernhard Kraatz and Sanela Martic |
title_short | Kinomics |
title_sort | kinomics approaches and applications |
title_sub | approaches and applications |
topic | Enzyminhibitor (DE-588)4152479-2 gnd Arzneimitteldesign (DE-588)4278218-1 gnd Kinasen (DE-588)4268693-3 gnd |
topic_facet | Enzyminhibitor Arzneimitteldesign Kinasen |
url | http://deposit.dnb.de/cgi-bin/dokserv?id=5200190&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028355699&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
work_keys_str_mv | AT kraatzheinzbernhard kinomicsapproachesandapplications AT marticsanela kinomicsapproachesandapplications |